- Conditions
- Chemotherapy Induced Nausea and Vomiting
- Interventions
- Olanzapine, Aprepitant
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–89
of 89
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ovarian Cancer, Uterine Cancer
- Interventions
- fosaprepitant, aprepitant, Oral Placebo, IV placebo
- Drug · Other
- Lead sponsor
- Gynecologic Oncology Associates
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Aprepitant 125 mg, Fosaprepitant 115 MG, Dexamethasone, Ondansetron 16 MG
- Drug
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- The Bronx, New York
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- Netupitant and Palonosetron, Aprepitant, Palonosetron, Dexamethasone
- Drug
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 11
- States / cities
- Muscle Shoals, Alabama • Burbank, California • Los Angeles, California + 8 more
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Casopitant (GW679769) Oral Tablets, dexamethasone, ondansetron
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Nausea, Vomiting
- Interventions
- Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract
- Other
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 21 Years to 89 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Oral GW679769, IV Cyclophosphamide 500-700mg/m2
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 3
- States / cities
- Newark, Delaware • Albuquerque, New Mexico • The Bronx, New York
- Conditions
- Multiple Myeloma, Autologous Stem Cell Transplantation
- Interventions
- Olanzapine
- Drug
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology
- Interventions
- Olanzapine, Placebo Oral Tablet
- Drug
- Lead sponsor
- The Hospital for Sick Children
- Other
- Eligibility
- 30 Months to 18 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 5
- States / cities
- San Francisco, California • Kansas City, Missouri • Chapel Hill, North Carolina + 2 more
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Casopitant 150 mg, Ketoconazole, Casopitant 150 mg matching placebo, Casopitant 50 mg, Casopitant 50 mg matching placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 3
- States / cities
- Overland Park, Kansas • Buffalo, New York • Columbus, Ohio
- Conditions
- Malignant Neoplasm
- Interventions
- Netupitant, Palonosetron Hydrochloride, Questionnaire Administration
- Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy, Adverse Effects of Medical Drugs
- Interventions
- Fosaprepitant, Dexamethasone, 5HT3 receptor antagonist, Ifosfamide-based chemotherapy (AI), Doxorubicin, Mesna, Ifosfamide, Vincristine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
- Interventions
- palonesetron
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 9
- States / cities
- Sunrise, Florida • Galesburg, Illinois • Skokie, Illinois + 6 more
- Conditions
- Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- fosaprepitant dimeglumine, systemic chemotherapy, survey administration, quality-of-life assessment
- Drug · Other · Procedure
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Chemotherapy-Related Nausea and/or Vomiting, Early Stage Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Interventions
- Biospecimen Collection, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 2 more
- Conditions
- Extrahepatic Bile Duct Cancer, Nausea, Vomiting, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Interventions
- aprepitant, gemcitabine hydrochloride, capecitabine, fluorouracil, radiation therapy, questionnaire administration, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications
- Drug · Procedure · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Casopitant (GW679769) oral tablets, Casopitant (GW679769) intravenous, Dexamethasone intravenous, Ondansetron oral tablets, placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Fayetteville, Arkansas + 78 more